Clinical Trial Update: Evaluation the Effect of Exjade on Oxidative Stress in Low Risk Myelodysplastic Syndrome Patients With Iron Over Load [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating the effect of Exjade (deferasirox) on oxidative stress in low-risk myelodysplastic syndrome patients with iron overload has completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• Exjade (deferasirox)

Snippet

Sponsor: Wolfson Medical Center | Conditions: Myelodysplastic Syndrome | Phase 4 | Status: COMPLETED